nach oben

Erschienen in:

08.02.2018 | Review Article

Exosomes in Pancreatic Cancer: from Early Detection to Treatment

verfasst von: Emily A. Armstrong, Eliza W. Beal, Jeffery Chakedis, Anghela Z. Paredes, Demetrios Moris, Timothy M. Pawlik, Carl R. Schmidt, Mary E. Dillhoff

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Pancreatic cancer (PC) remains one of the most fatal forms of cancer worldwide with incidence nearly equal to mortality. This is often attributed to the fact that diagnosis is often not made until later disease stages when treatment proves difficult. Efforts have been made to reduce the mortality of PC through improvements in early screening techniques and treatments of late-stage disease. Exosomes, small extracellular vesicles involved in cellular communication, have shown promise in helping understand PC disease biology.

Methods

In this review, we discuss current studies of the role of exosomes in PC physiology, and their potential use as diagnostic and treatment tools.

Results

Exosomes have a role in diagnosing pancreatic cancer and in understanding tumor biology including migration, proliferation, chemoresistance, immunosuppression, cachexia and diabetes, and have a potential role in therapy for pancreatic cancer.

Conclusions

Exosomal analysis is beneficial in demonstrating mechanisms behind PC growth and metastasis, immunosuppression, drug resistance, and paraneoplastic conditions. Furthermore, the use of exosomes can be beneficial in detecting early-stage PC and exosomes have potential applications as therapeutic targets.

Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. https://doi.org/10.3322/caac.21387.CrossRefPubMed

Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. Lancet. 2016;388(10039):73–85. https://doi.org/10.1016/S0140-6736(16)00141-0.CrossRefPubMed

Zhou B, Xu JW, Cheng YG, Gao JY, Hu SY, Wang L et al. Early detection of pancreatic cancer: Where are we now and where are we going? Int J Cancer. 2017;141(2):231–41. https://doi.org/10.1002/ijc.30670.CrossRefPubMed

Chiorean EG, Coveler AL. Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies. Drug Des Devel Ther. 2015;9:3529–45. https://doi.org/10.2147/DDDT.S60328.CrossRefPubMedPubMedCentral

Oberstein PE, Olive KP. Pancreatic cancer: why is it so hard to treat? Therap Adv Gastroenterol. 2013;6(4):321–37. https://doi.org/10.1177/1756283X13478680.CrossRefPubMedPubMedCentral

Mahadevan D, Von Hoff DD. Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther. 2007;6(4):1186–97. https://doi.org/10.1158/1535-7163.MCT-06-0686.CrossRefPubMed

Komar G, Kauhanen S, Liukko K, Seppänen M, Kajander S, Ovaska J et al. Decreased blood flow with increased metabolic activity: a novel sign of pancreatic tumor aggressiveness. Clin Cancer Res. 2009;15(17):5511–7. https://doi.org/10.1158/1078-0432.CCR-09-0414.CrossRefPubMed

Bergquist JR, Puig CA, Shubert CR, Groeschl RT, Habermann EB, Kendrick ML et al. Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and an Indication for Neoadjuvant Therapy: A National Cancer Database Study. J Am Coll Surg. 2016;223(1):52–65. https://doi.org/10.1016/j.jamcollsurg.2016.02.009.CrossRefPubMed

Gold B, Cankovic M, Furtado LV, Meier F, Gocke CD. Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? A report of the association for molecular pathology. J Mol Diagn. 2015;17(3):209–24. https://doi.org/10.1016/j.jmoldx.2015.02.001.CrossRefPubMedPubMedCentral

10.

Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004;10(20):6897–904. https://doi.org/10.1158/1078-0432.CCR-04-0378.CrossRefPubMed

11.

Sikora K, Bedin C, Vicentini C, Malpeli G, D’Angelo E, Sperandio N et al. Evaluation of cell-free DNA as a biomarker for pancreatic malignancies. Int J Biol Markers. 2015;30(1):e136–41. https://doi.org/10.5301/jbm.5000088. CrossRefPubMed

12.

Kishikawa T, Otsuka M, Ohno M, Yoshikawa T, Takata A, Koike K. Circulating RNAs as new biomarkers for detecting pancreatic cancer. World J Gastroenterol. 2015;21(28):8527–40. https://doi.org/10.3748/wjg.v21.i28.8527.CrossRefPubMedPubMedCentral

13.

Schwarzenbach H, Nishida N, Calin GA, Pantel K. Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol. 2014;11(3):145–56. https://doi.org/10.1038/nrclinonc.2014.5.CrossRefPubMed

14.

Di Leva G, Croce CM. miRNA profiling of cancer. Curr Opin Genet Dev. 2013;23(1):3–11. https://doi.org/10.1016/j.gde.2013.01.004.CrossRefPubMedPubMedCentral

15.

Ballehaninna UK, Chamberlain RS. Biomarkers for pancreatic cancer: promising new markers and options beyond CA 19-9. Tumour Biol. 2013;34(6):3279–92. https://doi.org/10.1007/s13277-013-1033-3.CrossRefPubMed

16.

Wu L, Qu X. Cancer biomarker detection: recent achievements and challenges. Chem Soc Rev. 2015;44(10):2963–97. https://doi.org/10.1039/c4cs00370e.CrossRefPubMed

17.

Shao Y, Shen Y, Chen T, Xu F, Chen X, Zheng S. The functions and clinical applications of tumor-derived exosomes. Oncotarget. 2016;7(37):60736–51. https://doi.org/10.18632/oncotarget.11177. CrossRefPubMedPubMedCentral

18.

Lin J, Li J, Huang B, Liu J, Chen X, Chen XM et al. Exosomes: novel biomarkers for clinical diagnosis. ScientificWorldJournal. 2015;2015:657086. https://doi.org/10.1155/2015/657086.PubMedPubMedCentral

19.

Schey KL, Luther JM, Rose KL. Proteomics characterization of exosome cargo. Methods. 2015;87:75–82. https://doi.org/10.1016/j.ymeth.2015.03.018.CrossRefPubMedPubMedCentral

20.

Tkach M, Théry C. Communication by Extracellular Vesicles: Where We Are and Where We Need to Go. Cell. 2016;164(6):1226–32. https://doi.org/10.1016/j.cell.2016.01.043.CrossRefPubMed

21.

Simpson RJ, Lim JW, Moritz RL, Mathivanan S. Exosomes: proteomic insights and diagnostic potential. Expert Rev Proteomics. 2009;6(3):267–83. https://doi.org/10.1586/epr.09.17.CrossRefPubMed

22.

Fong ZV, Winter JM. Biomarkers in pancreatic cancer: diagnostic, prognostic, and predictive. Cancer J. 2012;18(6):530–8. https://doi.org/10.1097/PPO.0b013e31827654ea.CrossRefPubMed

23.

Herreros-Villanueva M, Bujanda L. Non-invasive biomarkers in pancreatic cancer diagnosis: what we need versus what we have. Ann Transl Med. 2016;4(7):134. https://doi.org/10.21037/atm.2016.03.44.CrossRefPubMedPubMedCentral

24.

Chari ST, Kelly K, Hollingsworth MA, Thayer SP, Ahlquist DA, Andersen DK et al. Early detection of sporadic pancreatic cancer: summative review. Pancreas. 2015;44(5):693–712. https://doi.org/10.1097/MPA.0000000000000368.CrossRefPubMedPubMedCentral

25.

Zeringer E, Li M, Barta T, Schageman J, Pedersen KW, Neurauter A et al. Methods for the extraction and RNA profiling of exosomes. World J Methodol. 2013;3(1):11–8. https://doi.org/10.5662/wjm.v3.i1.11.CrossRefPubMedPubMedCentral

26.

Ayars M, Goggins M. Pancreatic cancer: Classifying pancreatic cancer using gene expression profiling. Nat Rev Gastroenterol Hepatol. 2015;12(11):613–4. https://doi.org/10.1038/nrgastro.2015.180.CrossRefPubMedPubMedCentral

27.

Caradec J, Kharmate G, Hosseini-Beheshti E, Adomat H, Gleave M, Guns E. Reproducibility and efficiency of serum-derived exosome extraction methods. Clin Biochem. 2014;47(13–14):1286–92. https://doi.org/10.1016/j.clinbiochem.2014.06.011.CrossRefPubMed

28.

Dreyer F, Baur A. Biogenesis and Functions of Exosomes and Extracellular Vesicles. Methods Mol Biol. 2016;1448:201–16. https://doi.org/10.1007/978-1-4939-3753-0_15.CrossRefPubMed

29.

Atay S, Godwin AK. Tumor-derived exosomes: A message delivery system for tumor progression. Commun Integr Biol. 2014;7(1):e28231. https://doi.org/10.4161/cib.28231.CrossRefPubMedPubMedCentral

30.

Greening DW, Xu R, Ji H, Tauro BJ, Simpson RJ. A protocol for exosome isolation and characterization: evaluation of ultracentrifugation, density-gradient separation, and immunoaffinity capture methods. Methods Mol Biol. 2015;1295:179–209. https://doi.org/10.1007/978-1-4939-2550-6_15.CrossRefPubMed

31.

Wang J, Yao Y, Wu J, Li G. Identification and analysis of exosomes secreted from macrophages extracted by different methods. Int J Clin Exp Pathol. 2015;8(6):6135–42.PubMedPubMedCentral

32.

McDonald MK, Tian Y, Qureshi RA, Gormley M, Ertel A, Gao R et al. Functional significance of macrophage-derived exosomes in inflammation and pain. Pain. 2014;155(8):1527–39. https://doi.org/10.1016/j.pain.2014.04.029. CrossRefPubMedPubMedCentral

33.

Kapustin AN, Shanahan CM. Emerging roles for vascular smooth muscle cell exosomes in calcification and coagulation. J Physiol. 2016;594(11):2905–14. https://doi.org/10.1113/JP271340.CrossRefPubMedPubMedCentral

34.

Ng YH, Rome S, Jalabert A, Forterre A, Singh H, Hincks CL et al. Endometrial exosomes/microvesicles in the uterine microenvironment: a new paradigm for embryo-endometrial cross talk at implantation. PLoS One. 2013;8(3):e58502. https://doi.org/10.1371/journal.pone.0058502.CrossRefPubMedPubMedCentral

35.

Wu CY, Du SL, Zhang J, Liang AL, Liu YJ. Exosomes and breast cancer: a comprehensive review of novel therapeutic strategies from diagnosis to treatment. Cancer Gene Ther. 2017;24(1):6–12. https://doi.org/10.1038/cgt.2016.69.CrossRefPubMed

36.

Cazzoli R, Buttitta F, Di Nicola M, Malatesta S, Marchetti A, Rom WN et al. microRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer. J Thorac Oncol. 2013;8(9):1156–62. https://doi.org/10.1097/JTO.0b013e318299ac32.CrossRefPubMedPubMedCentral

37.

Ogata-Kawata H, Izumiya M, Kurioka D, Honma Y, Yamada Y, Furuta K et al. Circulating exosomal microRNAs as biomarkers of colon cancer. PLoS One. 2014;9(4):e92921. https://doi.org/10.1371/journal.pone.0092921.CrossRefPubMedPubMedCentral

38.

Moris D, Beal EW, Chakedis J, Burkhart RA, Schmidt C, Dillhoff M et al. Role of exosomes in treatment of hepatocellular carcinoma. Surg Oncol. 2017;26(3):219–28. https://doi.org/10.1016/j.suronc.2017.04.005.CrossRefPubMed

39.

André MoR, Pedro A, Lyden D. Cancer Exosomes as Mediators of Drug Resistance. Methods Mol Biol. 2016;1395:229–39. https://doi.org/10.1007/978-1-4939-3347-1_13.CrossRef

40.

Jin H, Wu Y, Tan X. The role of pancreatic cancer-derived exosomes in cancer progress and their potential application as biomarkers. Clin Transl Oncol. 2017;19(8):921–30. https://doi.org/10.1007/s12094-017-1625-2.CrossRefPubMed

41.

Kourembanas S. Exosomes: vehicles of intercellular signaling, biomarkers, and vectors of cell therapy. Annu Rev Physiol. 2015;77:13–27. https://doi.org/10.1146/annurev-physiol-021014-071641.CrossRefPubMed

42.

Masyuk AI, Masyuk TV, Larusso NF. Exosomes in the pathogenesis, diagnostics and therapeutics of liver diseases. J Hepatol. 2013;59(3):621–5. https://doi.org/10.1016/j.jhep.2013.03.028.CrossRefPubMed

43.

Gui Y, Liu H, Zhang L, Lv W, Hu X. Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease. Oncotarget. 2015;6(35):37043–53. https://doi.org/10.18632/oncotarget.6158. CrossRefPubMedPubMedCentral

44.

Rekker K, Saare M, Roost AM, Kubo AL, Zarovni N, Chiesi A et al. Comparison of serum exosome isolation methods for microRNA profiling. Clin Biochem. 2014;47(1–2):135–8. https://doi.org/10.1016/j.clinbiochem.2013.10.020.CrossRefPubMed

45.

Tjensvoll K, Nordgård O, Smaaland R. Circulating tumor cells in pancreatic cancer patients: methods of detection and clinical implications. Int J Cancer. 2014;134(1):1–8. https://doi.org/10.1002/ijc.28134.CrossRefPubMed

46.

Takai E, Totoki Y, Nakamura H, Morizane C, Nara S, Hama N et al. Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer. Sci Rep. 2015;5:18425. https://doi.org/10.1038/srep18425.CrossRefPubMedPubMedCentral

47.

Poruk KE, Gay DZ, Brown K, Mulvihill JD, Boucher KM, Scaife CL et al. The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates. Curr Mol Med. 2013;13(3):340–51.PubMedPubMedCentral

48.

San Lucas FA, Allenson K, Bernard V, Castillo J, Kim DU, Ellis K et al. Minimally invasive genomic and transcriptomic profiling of visceral cancers by next-generation sequencing of circulating exosomes. Ann Oncol. 2016;27(4):635–41. https://doi.org/10.1093/annonc/mdv604.CrossRefPubMed

49.

Gallo A, Tandon M, Alevizos I, Illei GG. The majority of microRNAs detectable in serum and saliva is concentrated in exosomes. PLoS One. 2012;7(3):e30679. https://doi.org/10.1371/journal.pone.0030679.CrossRefPubMedPubMedCentral

50.

Endzeliņš E, Berger A, Melne V, Bajo-Santos C, Soboļevska K, Ābols A et al. Detection of circulating miRNAs: comparative analysis of extracellular vesicle-incorporated miRNAs and cell-free miRNAs in whole plasma of prostate cancer patients. BMC Cancer. 2017;17(1):730. https://doi.org/10.1186/s12885-017-3737-z. CrossRefPubMedPubMedCentral

51.

Nakamura K, Sawada K, Yoshimura A, Kinose Y, Nakatsuka E, Kimura T. Clinical relevance of circulating cell-free microRNAs in ovarian cancer. Mol Cancer. 2016;15(1):48. https://doi.org/10.1186/s12943-016-0536-0. CrossRefPubMedPubMedCentral

52.

Kahlert C, Melo SA, Protopopov A, Tang J, Seth S, Koch M et al. Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer. J Biol Chem. 2014;289(7):3869–75. https://doi.org/10.1074/jbc.C113.532267.CrossRefPubMedPubMedCentral

53.

Yang S, Che SP, Kurywchak P, Tavormina JL, Gansmo LB, Correa de Sampaio P et al. Detection of mutant KRAS and TP53 DNA in circulating exosomes from healthy individuals and patients with pancreatic cancer. Cancer Biol Ther. 2017;18(3):158–65. https://doi.org/10.1080/15384047.2017.1281499.CrossRefPubMedPubMedCentral

54.

Allenson K, Castillo J, San Lucas FA, Scelo G, Kim DU, Bernard V et al. High Prevalence of Mutant KRAS in Circulating Exosome-derived DNA from Early Stage Pancreatic Cancer Patients. Ann Oncol. 2017. https://doi.org/10.1093/annonc/mdx004.

55.

Lorenzon L, Blandino G. Glypican-1 exosomes: do they initiate a new era for early pancreatic cancer diagnosis? Transl Gastroenterol Hepatol. 2016;1:8. https://doi.org/10.21037/tgh.2016.01.07.CrossRefPubMedPubMedCentral

56.

Melo SA, Luecke LB, Kahlert C, Fernandez AF, Gammon ST, Kaye J et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature. 2015;523(7559):177–82. https://doi.org/10.1038/nature14581.CrossRefPubMedPubMedCentral

57.

Lai X, Wang M, McElyea SD, Sherman S, House M, Korc M. A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer. Cancer Lett. 2017;393:86–93. https://doi.org/10.1016/j.canlet.2017.02.019. CrossRefPubMedPubMedCentral

58.

Que R, Ding G, Chen J, Cao L. Analysis of serum exosomal microRNAs and clinicopathologic features of patients with pancreatic adenocarcinoma. World J Surg Oncol. 2013;11:219. https://doi.org/10.1186/1477-7819-11-219.CrossRefPubMedPubMedCentral

59.

Machida T, Tomofuji T, Maruyama T, Yoneda T, Ekuni D, Azuma T et al. miR-1246 and miR-4644 in salivary exosome as potential biomarkers for pancreatobiliary tract cancer. Oncol Rep. 2016;36(4):2375–81. https://doi.org/10.3892/or.2016.5021.CrossRefPubMed

60.

Madhavan B, Yue S, Galli U, Rana S, Gross W, Müller M et al. Combined evaluation of a panel of protein and miRNA serum-exosome biomarkers for pancreatic cancer diagnosis increases sensitivity and specificity. Int J Cancer. 2015;136(11):2616–27. https://doi.org/10.1002/ijc.29324.CrossRefPubMed

61.

Lau C, Kim Y, Chia D, Spielmann N, Eibl G, Elashoff D et al. Role of pancreatic cancer-derived exosomes in salivary biomarker development. J Biol Chem. 2013;288(37):26888–97. https://doi.org/10.1074/jbc.M113.452458.CrossRefPubMedPubMedCentral

62.

Hui L, Chen Y. Tumor microenvironment: Sanctuary of the devil. Cancer Lett. 2015;368(1):7–13. https://doi.org/10.1016/j.canlet.2015.07.039.CrossRefPubMed

63.

Milane L, Singh A, Mattheolabakis G, Suresh M, Amiji MM. Exosome mediated communication within the tumor microenvironment. J Control Release. 2015;219:278–94. https://doi.org/10.1016/j.jconrel.2015.06.029.CrossRefPubMed

64.

Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Tesic Mark M et al. Tumour exosome integrins determine organotropic metastasis. Nature. 2015;527(7578):329–35. https://doi.org/10.1038/nature15756.CrossRefPubMedPubMedCentral

65.

Nuzhat Z, Kinhal V, Sharma S, Rice GE, Joshi V, Salomon C. Tumour-derived exosomes as a signature of pancreatic cancer - liquid biopsies as indicators of tumour progression. Oncotarget. 2016. https://doi.org/10.18632/oncotarget.13973.

66.

Patel GK, Patton MC, Singh S, Khushman M, Singh AP. Pancreatic Cancer Exosomes: Shedding Off for a Meaningful Journey. Pancreat Disord Ther. 2016;6(2):e148. https://doi.org/10.4172/2165-7092.1000e148.CrossRefPubMedPubMedCentral

67.

Harada T, Yamamoto H, Kishida S, Kishida M, Awada C, Takao T et al. Wnt5b-associated exosomes promote cancer cell migration and proliferation. Cancer Sci. 2017;108(1):42–52. https://doi.org/10.1111/cas.13109.CrossRefPubMed

68.

Wang Z, von Au A, Schnölzer M, Hackert T, Zöller M. CD44v6-competent tumor exosomes promote motility, invasion and cancer-initiating cell marker expression in pancreatic and colorectal cancer cells. Oncotarget. 2016;7(34):55409–36. https://doi.org/10.18632/oncotarget.10580. PubMedPubMedCentral

69.

Chen D, Wu X, Xia M, Wu F, Ding J, Jiao Y et al. Upregulated exosomic miR-23b-3p plays regulatory roles in the progression of pancreatic cancer. Oncol Rep. 2017;38(4):2182–8. https://doi.org/10.3892/or.2017.5919.CrossRefPubMedPubMedCentral

70.

Takikawa T, Masamune A, Yoshida N, Hamada S, Kogure T, Shimosegawa T. Exosomes Derived From Pancreatic Stellate Cells: MicroRNA Signature and Effects on Pancreatic Cancer Cells. Pancreas. 2017;46(1):19–27. https://doi.org/10.1097/MPA.0000000000000722.CrossRefPubMed

71.

Ali S, Suresh R, Banerjee S, Bao B, Xu Z, Wilson J et al. Contribution of microRNAs in understanding the pancreatic tumor microenvironment involving cancer associated stellate and fibroblast cells. Am J Cancer Res. 2015;5(3):1251–64.PubMedPubMedCentral

72.

Yu Z, Zhao S, Ren L, Wang L, Chen Z, Hoffman RM et al. Pancreatic cancer-derived exosomes promote tumor metastasis and liver pre-metastatic niche formation. Oncotarget. 2017;8(38):63461–83. https://doi.org/10.18632/oncotarget.18831.PubMedPubMedCentral

73.

Costa-Silva B, Aiello NM, Ocean AJ, Singh S, Zhang H, Thakur BK et al. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat Cell Biol. 2015;17(6):816–26. https://doi.org/10.1038/ncb3169.CrossRefPubMedPubMedCentral

74.

Yoneyama H, Takizawa-Hashimoto A, Takeuchi O, Watanabe Y, Atsuda K, Asanuma F et al. Acquired resistance to gemcitabine and cross-resistance in human pancreatic cancer clones. Anticancer Drugs. 2015;26(1):90–100. https://doi.org/10.1097/CAD.0000000000000165.CrossRefPubMed

75.

Hu H, Gu Y, Qian Y, Hu B, Zhu C, Wang G et al. DNA-PKcs is important for Akt activation and gemcitabine resistance in PANC-1 pancreatic cancer cells. Biochem Biophys Res Commun. 2014;452(1):106–11. https://doi.org/10.1016/j.bbrc.2014.08.059.CrossRefPubMed

76.

Binenbaum Y, Na'ara S, Gil Z. Gemcitabine resistance in pancreatic ductal adenocarcinoma. Drug Resist Updat. 2015;23:55–68. https://doi.org/10.1016/j.drup.2015.10.002.CrossRefPubMed

77.

Mikamori M, Yamada D, Eguchi H, Hasegawa S, Kishimoto T, Tomimaru Y et al. MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma. Sci Rep. 2017;7:42339. https://doi.org/10.1038/srep42339.CrossRefPubMedPubMedCentral

78.

Patel GK, Khan MA, Bhardwaj A, Srivastava SK, Zubair H, Patton MC et al. Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCK. Br J Cancer. 2017;116(5):609–19. https://doi.org/10.1038/bjc.2017.18.CrossRefPubMedPubMedCentral

79.

Beloribi-Djefaflia S, Siret C, Lombardo D. Exosomal lipids induce human pancreatic tumoral MiaPaCa-2 cells resistance through the CXCR4-SDF-1α signaling axis. Oncoscience. 2015;2(1):15–30. https://doi.org/10.18632/oncoscience.96. PubMed

80.

Bhattacharya S, Pal K, Sharma AK, Dutta SK, Lau JS, Yan IK et al. GAIP interacting protein C-terminus regulates autophagy and exosome biogenesis of pancreatic cancer through metabolic pathways. PLoS One. 2014;9(12):e114409. https://doi.org/10.1371/journal.pone.0114409.CrossRefPubMedPubMedCentral

81.

Richards KE, Zeleniak AE, Fishel ML, Wu J, Littlepage LE, Hill R. Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells. Oncogene. 2017;36(13):1770–8. https://doi.org/10.1038/onc.2016.353.CrossRefPubMed

82.

Kahlert C, Kalluri R. Exosomes in tumor microenvironment influence cancer progression and metastasis. J Mol Med (Berl). 2013;91(4):431–7. https://doi.org/10.1007/s00109-013-1020-6.CrossRefPubMedPubMedCentral

83.

Chen W, Jiang J, Xia W, Huang J. Tumor-Related Exosomes Contribute to Tumor-Promoting Microenvironment: An Immunological Perspective. J Immunol Res. 2017;2017:1073947. https://doi.org/10.1155/2017/1073947.PubMedPubMedCentral

84.

Ding G, Zhou L, Qian Y, Fu M, Chen J, Xiang J et al. Pancreatic cancer-derived exosomes transfer miRNAs to dendritic cells and inhibit RFXAP expression via miR-212-3p. Oncotarget. 2015;6(30):29877–88. https://doi.org/10.18632/oncotarget.4924. CrossRefPubMedPubMedCentral

85.

Zhou M, Chen J, Zhou L, Chen W, Ding G, Cao L. Pancreatic cancer derived exosomes regulate the expression of TLR4 in dendritic cells via miR-203. Cell Immunol. 2014;292(1–2):65–9. https://doi.org/10.1016/j.cellimm.2014.09.004.CrossRefPubMed

86.

Que RS, Lin C, Ding GP, Wu ZR, Cao LP. Increasing the immune activity of exosomes: the effect of miRNA-depleted exosome proteins on activating dendritic cell/cytokine-induced killer cells against pancreatic cancer. J Zhejiang Univ Sci B. 2016;17(5):352–60. https://doi.org/10.1631/jzus.B1500305.CrossRefPubMedPubMedCentral

87.

Katsiougiannis S, Chia D, Kim Y, Singh RP, Wong DT. Saliva exosomes from pancreatic tumor-bearing mice modulate NK cell phenotype and antitumor cytotoxicity. FASEB J. 2017;31(3):998–1010. https://doi.org/10.1096/fj.201600984R.CrossRefPubMed

88.

Javeed N, Sagar G, Dutta SK, Smyrk TC, Lau JS, Bhattacharya S et al. Pancreatic Cancer-Derived Exosomes Cause Paraneoplastic β-cell Dysfunction. Clin Cancer Res. 2015;21(7):1722–33. https://doi.org/10.1158/1078-0432.CCR-14-2022.CrossRefPubMed

89.

Sagar G, Sah RP, Javeed N, Dutta SK, Smyrk TC, Lau JS et al. Pathogenesis of pancreatic cancer exosome-induced lipolysis in adipose tissue. Gut. 2016;65(7):1165–74. https://doi.org/10.1136/gutjnl-2014-308350.CrossRefPubMed

90.

Wang L, Zhang B, Zheng W, Kang M, Chen Q, Qin W et al. Exosomes derived from pancreatic cancer cells induce insulin resistance in C2C12 myotube cells through the PI3K/Akt/FoxO1 pathway. Sci Rep. 2017;7(1):5384. https://doi.org/10.1038/s41598-017-05541-4. CrossRefPubMedPubMedCentral

91.

Kim SM, Kim HS. Engineering of extracellular vesicles as drug delivery vehicles. Stem Cell Investig. 2017;4:74. https://doi.org/10.21037/sci.2017.08.07.CrossRefPubMedPubMedCentral

92.

Haney MJ, Klyachko NL, Zhao Y, Gupta R, Plotnikova EG, He Z et al. Exosomes as drug delivery vehicles for Parkinson's disease therapy. J Control Release. 2015;207:18–30. https://doi.org/10.1016/j.jconrel.2015.03.033.CrossRefPubMedPubMedCentral

93.

Tan A, Rajadas J, Seifalian AM. Exosomes as nano-theranostic delivery platforms for gene therapy. Adv Drug Deliv Rev. 2013;65(3):357–67. https://doi.org/10.1016/j.addr.2012.06.014.CrossRefPubMed

94.

Tian Y, Li S, Song J, Ji T, Zhu M, Anderson GJ et al. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials. 2014;35(7):2383–90. https://doi.org/10.1016/j.biomaterials.2013.11.083.CrossRefPubMed

95.

Tang K, Zhang Y, Zhang H, Xu P, Liu J, Ma J et al. Delivery of chemotherapeutic drugs in tumour cell-derived microparticles. Nat Commun. 2012;3:1282. https://doi.org/10.1038/ncomms2282.CrossRefPubMed

96.

Batrakova EV, Kim MS. Using exosomes, naturally-equipped nanocarriers, for drug delivery. J Control Release. 2015;219:396–405. https://doi.org/10.1016/j.jconrel.2015.07.030.CrossRefPubMedPubMedCentral

97.

Wang M, Altinoglu S, Takeda YS, Xu Q. Integrating Protein Engineering and Bioorthogonal Click Conjugation for Extracellular Vesicle Modulation and Intracellular Delivery. PLoS One. 2015;10(11):e0141860. https://doi.org/10.1371/journal.pone.0141860.CrossRefPubMedPubMedCentral

98.

Su MJ, Aldawsari H, Amiji M. Pancreatic Cancer Cell Exosome-Mediated Macrophage Reprogramming and the Role of MicroRNAs 155 and 125b2 Transfection using Nanoparticle Delivery Systems. Sci Rep. 2016;6:30110. https://doi.org/10.1038/srep30110.CrossRefPubMedPubMedCentral

99.

Mahmoodzadeh Hosseini H, Ali Imani Fooladi A, Soleimanirad J, Reza Nourani M, Mahdavi M. Exosome/staphylococcal enterotoxin B, an anti tumor compound against pancreatic cancer. J BUON. 2014;19(2):440–8.PubMed

100.

Aspe JR, Diaz Osterman CJ, Jutzy JM, Deshields S, Whang S, Wall NR. Enhancement of Gemcitabine sensitivity in pancreatic adenocarcinoma by novel exosome-mediated delivery of the Survivin-T34A mutant. J Extracell Vesicles. 2014;3. https://doi.org/10.3402/jev.v3.23244.

101.

Mrizak D, Martin N, Barjon C, Jimenez-Pailhes AS, Mustapha R, Niki T et al. Effect of nasopharyngeal carcinoma-derived exosomes on human regulatory T cells. J Natl Cancer Inst. 2015;107(1):363. https://doi.org/10.1093/jnci/dju363.CrossRefPubMed

102.

Whiteside TL. Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes). Biochem Soc Trans. 2013;41(1):245–51. https://doi.org/10.1042/BST20120265.CrossRefPubMedPubMedCentral

103.

Taller D, Richards K, Slouka Z, Senapati S, Hill R, Go DB et al. On-chip surface acoustic wave lysis and ion-exchange nanomembrane detection of exosomal RNA for pancreatic cancer study and diagnosis. Lab Chip. 2015;15(7):1656–66. https://doi.org/10.1039/c5lc00036j.CrossRefPubMed

Titel: Exosomes in Pancreatic Cancer: from Early Detection to Treatment
verfasst von: Emily A. Armstrong
Eliza W. Beal
Jeffery Chakedis
Anghela Z. Paredes
Demetrios Moris
Timothy M. Pawlik
Carl R. Schmidt
Mary E. Dillhoff
Publikationsdatum: 08.02.2018
Verlag: Springer US
Erschienen in: Journal of Gastrointestinal Surgery / Ausgabe 4/2018
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI: https://doi.org/10.1007/s11605-018-3693-1

Neu im Fachgebiet Chirurgie

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 | Appendizitis | Nachrichten

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 | Operationsvorbereitung | Nachrichten

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Ureterstriktur: Innovative OP-Technik bewährt sich

weitere anzeigen

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2018

Incidence and Risk Factors of Cholangitis after Hepaticojejunostomy

Solitary Plexiform Neurofibroma of the Hepatic Artery

Laparoscopic Treatment of Median Arcuate Ligament Syndrome: Analysis of Long-Term Outcomes and Predictive Factors

Association of Adjuvant Therapy with Improved Survival in Ampullary Cancer: A National Cohort Study

Response to: Would Dedicated Emergency Surgery Professionals Improve the Emergency General Surgery Service and Reduce the “Weekend Effect”?

Letter to the Editor: Utility of Endoanal Ultrasonography in Assessment of Primary and Recurrent Anal Fistulas and for Detection of Associated Anal Sphincter Defects

Neu im Fachgebiet Chirurgie

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Hinter dieser Appendizitis steckte ein Erreger

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

Ureterstriktur: Innovative OP-Technik bewährt sich

Update Chirurgie

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

S2e-Leitlinie „Distale Radiusfraktur“

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“